In response to the COVID-19 pandemic, researchers at the University of
Pittsburgh raised a panel of high-affinity SARS-CoV-2 nanobodies. To develop a
potent SARS-CoV-2 neutralizing cocktail for rapid development, the team
required a safe and fast method to screen these molecules for virus-neutralizing
SARS-CoV-2 Reporter Virus Particles Enable Rapid Selection of Potent Neutralizing Nanobodies
Integral Molecular’s quality-controlled SARS-CoV-2 Reporter Virus Particles (RVPs) enabled safe (BSL-2), easy, and high-throughput assessment of SARS-CoV-2 nanobodies. RVP-based neutralization assays enabled the selection of three nanobody candidates with exceptional neutralizing potency.
Fourteen of the most potent antibodies were assayed for neutralization using both luciferase RVPs and live infectious SARS-CoV-2 virus by plaque reduction neutralization testing (PRNT).
RVP neutralization assay results directly correlated with Plaque Reduction Neutralization Tests (PRNT) using live virus, with R2 = 0.92.